• HEALEY ALS Platform Trial Regimen I expanded to 250 participants
• Long-term supply agreement with Elanco Animal Health
• New preclinical data presented at BIO International Convention 2026
• Board strengthened with Dr Ross Murdoch's appointment
• Strategic R&D financing facility of up to $17.5 million established

Neurizon Therapeutics Limited (ASX: NUZ) reported significant progress in its Q4 FY26 activities, highlighted by the expansion of its HEALEY ALS Platform Trial Regimen I to 250 participants, which is anticipated to accelerate topline efficacy and safety results to late Q4 FY2027. The expansion was achieved without increasing funding requirements, reflecting effective execution and support from the Sean M. Healey & AMG Center for ALS. Neurizon also secured a long-term supply agreement with Elanco Animal Health, ensuring GMP supply of the active pharmaceutical ingredient in NUZ-001. New preclinical data presented at BIO International Convention 2026 further supported the scientific rationale for NUZ-001. The company further strengthened its board with the appointment of Dr Ross Murdoch as an Independent Non-Executive Director, enhancing clinical development and commercial expertise. Neurizon also established a strategic R&D financing facility of up to $17.5 million, providing immediate access to capital earned through its investment in eligible R&D activities.

Topline efficacy and safety results expected in late Q4 FY2027

Neurizon remains focused on executing the trial, generating high-quality data, and advancing NUZ-001 for potential commercialization.